Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00291876
First received: February 14, 2006
Last updated: May 1, 2014
Last verified: April 2014
Results First Received: December 10, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Hepatitis A
Intervention: Biological: Havrix™

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Participant Flow and Baseline measures are given for the Month 198 time point in order to account for all subjects participating in this long-term follow-up study.

Note that not all subjects returned and participated in each of the intermediate follow-up time points.


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

The Long-Term (LT) Total Cohort included all subjects who returned for the follow-up and who belonged to the Total Cohort in the primary study.

The Long Term According-to-Protocol (LT-ATP) cohort for immunogenicity included subjects who returned for the follow-up and who were included in the ATP cohort for immunogenicity of the primary study.


Reporting Groups
  Description
Havrix Group Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.

Participant Flow for 10 periods

Period 1:   Month 138
    Havrix Group  
STARTED     107  
COMPLETED     107  
NOT COMPLETED     0  

Period 2:   Month 150
    Havrix Group  
STARTED     117  
COMPLETED     117  
NOT COMPLETED     0  

Period 3:   Month 162
    Havrix Group  
STARTED     127  
COMPLETED     127  
NOT COMPLETED     0  

Period 4:   Month 174
    Havrix Group  
STARTED     127  
COMPLETED     127  
NOT COMPLETED     0  

Period 5:   Month 186
    Havrix Group  
STARTED     129  
COMPLETED     129  
NOT COMPLETED     0  

Period 6:   Month 198
    Havrix Group  
STARTED     135  
COMPLETED     135  
NOT COMPLETED     0  

Period 7:   Month 210
    Havrix Group  
STARTED     124  
COMPLETED     124  
NOT COMPLETED     0  

Period 8:   Month 222
    Havrix Group  
STARTED     114  
COMPLETED     114  
NOT COMPLETED     0  

Period 9:   Month 234
    Havrix Group  
STARTED     110  
COMPLETED     110  
NOT COMPLETED     0  

Period 10:   Month 246
    Havrix Group  
STARTED     116  
COMPLETED     116  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Havrix Group Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.

Baseline Measures
    Havrix Group  
Number of Participants  
[units: participants]
  135  
Age [1]
[units: Years]
Mean ± Standard Deviation
  42.2  ± 5.44  
Age [2]
[units: Years]
Mean ± Standard Deviation
  42.9  ± 5.35  
Age [3]
[units: Years]
Mean ± Standard Deviation
  43.4  ± 5.34  
Age [4]
[units: Years]
Mean ± Standard Deviation
  44.5  ± 5.37  
Age [5]
[units: Years]
Mean ± Standard Deviation
  45.4  ± 5.39  
Age [6]
[units: Years]
Mean ± Standard Deviation
  46.3  ± 5.35  
Age [7]
[units: Years]
Mean ± Standard Deviation
  47.6  ± 5.39  
Age [8]
[units: Years]
Mean ± Standard Deviation
  48.5  ± 5.39  
Age [9]
[units: Years]
Mean ± Standard Deviation
  49.6  ± 5.42  
Age [10]
[units: Years]
Mean ± Standard Deviation
  50.8  ± 5.34  
Gender [1]
[units: Subjects]
 
Female     77  
Male     30  
Gender [2]
[units: Subjects]
 
Female     87  
Male     30  
Gender [3]
[units: Subjects]
 
Female     93  
Male     34  
Gender [4]
[units: Subjects]
 
Female     94  
Male     33  
Gender [5]
[units: Subjects]
 
Female     98  
Male     31  
Gender [6]
[units: Subjects]
 
Female     103  
Male     32  
Gender [6]
[units: Subjects]
 
Female     93  
Male     31  
Gender [8]
[units: Subjects]
 
Female     83  
Male     31  
Gender [9]
[units: Subjects]
 
Female     81  
Male     29  
Gender [10]
[units: Subjects]
 
Female     86  
Male     30  
[1] The baseline measure data here corresponds to Month 138
[2] The baseline measure data here corresponds to Month 150
[3] The baseline measure data here corresponds to Month 162
[4] The baseline measure data here corresponds to Month 174
[5] The baseline measure data here corresponds to Month 186
[6] The baseline measure data here corresponds to Month 198
[7] The baseline measure data here corresponds to Month 210
[8] The baseline measure data here corresponds to Month 222
[9] The baseline measure data here corresponds to Month 234
[10] The baseline measure data here corresponds to Month 246



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration   [ Time Frame: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246 ]

2.  Primary:   Number of Seropositive Subjects Against Hepatitis A Virus   [ Time Frame: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246 ]

3.  Secondary:   Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration   [ Time Frame: Before additional vaccination, 14 days after additional vaccination and 30 days after additional vaccination ]

4.  Secondary:   Number of Subjects Reporting Solicited Local Symptoms   [ Time Frame: During the 4-day (Days 0-3) follow-up period after additional vaccination ]

5.  Secondary:   Number of Subjects Reporting Solicited General Symptoms   [ Time Frame: During the 4-day (Days 0-3) follow-up period after additional vaccination ]

6.  Secondary:   Number of Subjects Reporting Unsolicited Adverse Events (AE)   [ Time Frame: During the 30-day follow-up period after additional vaccination ]

7.  Secondary:   Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigator as Related to Primary Study Vaccination, Procedures or Lack of Vaccine Efficacy   [ Time Frame: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246 ]

8.  Secondary:   Number of Subjects Reporting Serious Adverse Events (SAE) After Additional Vaccination   [ Time Frame: During the 30-day follow-up period after additional vaccination ]

9.  Secondary:   Number of Subjects Reporting Pregnancies After Additional Vaccination   [ Time Frame: At Months 186 and 198 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
For 5 subjects at Month 234, serum sample tubes were broken. Due to risk of contamination, anti-HAV concentrations analyses were not performed for these subjects, who were excluded in the LT-ATP cohort for immunogenicity analysis at Month 234.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


Publications:
Van Herck K et al. (2011) Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol. 83(11):1885-1891.

Publications automatically indexed to this study:

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00291876     History of Changes
Other Study ID Numbers: 100571 (M138), 100572 (M150), 100573 (M162), 100574 (M174), 100575 (M186), 110677 (M198), 110678 (M210), 110679, 110680, 110681
Study First Received: February 14, 2006
Results First Received: December 10, 2009
Last Updated: May 1, 2014
Health Authority: Belgium: Institutional Review Board